

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 November 2006 (30.11.2006)

PCT

(10) International Publication Number
WO 2006/126939 A1

(51) International Patent Classification:

C07C 311/08 (2006.01)	C07D 233/84 (2006.01)
A61K 31/18 (2006.01)	C07D 311/04 (2006.01)
A61K 31/35 (2006.01)	C07D 333/34 (2006.01)
A61K 31/381 (2006.01)	C07D 401/12 (2006.01)
A61P 25/16 (2006.01)	C07D 405/12 (2006.01)
A61P 25/18 (2006.01)	C07D 407/12 (2006.01)
A61P 25/28 (2006.01)	C07D 409/12 (2006.01)
C07C 311/14 (2006.01)	C07D 409/14 (2006.01)
C07C 311/21 (2006.01)	C07D 413/04 (2006.01)
C07D 213/71 (2006.01)	C07D 413/12 (2006.01)
C07D 215/36 (2006.01)	C07D 413/14 (2006.01)

[US/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **VON BERG, Stefan** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:

PCT/SE2006/000593

(22) International Filing Date: 22 May 2006 (22.05.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0501166-3	23 May 2005 (23.05.2005)	SE
0501168-9	23 May 2005 (23.05.2005)	SE

(71) Applicant (*for all designated States except US*): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CHU, Chester** [GB/GB]; 177 Tuckers Road, Loughborough Leicestershire LE11 2PH (GB). **LISTER, Andrew** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **NORDVALL, Gunnar** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **PETERSSON, Carl** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **ROTTICCI, Didier** [FR/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **SOHN, Daniel**

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(48) Date of publication of this corrected version:


7 June 2007

(15) Information about Correction:

see PCT Gazette No. 23/2007 of 7 June 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR



(I)

(57) Abstract: The present invention relates to new compounds of formula I. (I) wherein R^1 to R^{12} , P, X, Q and n are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.